Download the papers from the Lancet Neurology website2
(registration to gain open access to the papers is free)

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

Plain English summary of the IST-3 findings

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis


Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial

Additional material - follow these links


Press releases

IST-3 Media Coverage

Link to slides at ESC Lisbon  and ESC London

Trial publications 2016

Trial protocol
Statistical analysis plan
Apply for access to the data set
Lists of the members of the collaborative group
Funding sources

  Follow IST-3 on Twitter: @IST_3